Cholestasis, including primary biliary cirrhosis (PBC) and primary sclerosing cholangitis
(PSC), results from an impairment or disruption of bile production and causes intracellular …

Recent progress in basic research has enhanced our understanding of the molecular
mechanisms of normal bile secretion and their alterations in cholestasis. Genetic transporter …

Primary biliary cholangitis (PBC) is a chronic inflammatory autoimmune cholestatic liver
disease, which when untreated will culminate in end-stage biliary cirrhosis. Diagnosis is …

Primary biliary cholangitis (formerly known as primary biliary cirrhosis, PBC) is an
autoimmune liver disease in which a cycle of immune mediated biliary epithelial cell injury …

Metabolic processes utilize a variety of differing and contrasting biochemical routes to
enable synthesis of degradation and activation or deactivation of substances; in addition …

Hepatic uptake and biliary excretion of organic anions (eg, bile acids and bilirubin) is
mediated by hepatobiliary transport systems. Defects in transporter expression and function …

Like several other ATP-binding cassette (ABC) transporters, ABCB4 is a lipid translocator. It
translocates phosphatidylcholine (PC) from the inner to the outer leaflet of the canalicular …

OBJECTIVES: Adding fibrates improves liver biochemistries in patients with primary biliary
cholangitis (PBC) and suboptimal response to ursodeoxycholic acid (UDCA). As there are …

Aliment Pharmacol Ther 2011; 33: 235–242 Summary Background Newer therapies are
needed for patients with primary biliary cirrhosis and incomplete response to …

In Japan, bezafibrate (BF) is a second‐line agent for primary biliary cholangitis (PBC) that is
refractory to ursodeoxycholic acid (UDCA) treatment. From a retrospective cohort (n= 873) …